AtriCure (ATRC)
Makes surgical cardiac ablation, AtriClip appendage exclusion, and cryo nerve block devices.
Something off on this page? Send us feedback.
Sells surgical devices for cardiac tissue ablation, left atrial appendage exclusion, and temporary nerve ablation for post-operative pain control. Revenue is reported as a unified operating segment, concentrated in the United States, with growth tied to pain management, open ablation, appendage management, clinical evidence, and physician education.
Develops, manufactures, and sells devices used in cardiac and thoracic procedures: open and minimally invasive ablation systems, Hybrid AF Therapy with EPi-Sense, AtriClip left atrial appendage exclusion devices, cryo nerve block products, epicardial access, and related surgical instruments.
Revenue is reported as a single operating segment with product-line detail rather than separate reportable businesses. Sales are concentrated in the United States, while the product portfolio also reaches international hospitals and specialists.
Execution centers on product innovation, clinical science, and physician education. Current growth has been tied to pain management, open ablation, and appendage management; minimally invasive ablation has faced pressure as physicians adopted pulsed-field ablation catheters.
The business depends on FDA-cleared or approved indications, surgeon adoption, clinical trial evidence, and hospital procedure volumes.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Needham | Reiterate | Buy | $40 | $64 | |
| Aug 27, 2026 | Piper Sandler | Reiterate | Overweight | $40 | $60 | |
| Aug 24, 2026 | BTIG | Reiterate | Buy | $54 | $55 | |
| Jul 28, 2026 | UBS | Reiterate | Buy | $55 | $50 | |
| Jul 21, 2026 | Raymond James | Target | $52 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $167.8M · Total debt $71.0M · Total assets $676.6M · Shareholders' equity $516.4M
- Revenue
- $153.6M
- Operating income
- $9.7M
- Net income
- $9.0M
No dividends on record.
| Institutions261 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 102.58% | 52.18M shares | |
| Insiders16 holders · as of Aug 26, 2026 | 4.01% | 2.04M shares | |
| Strategic holders1 holder · as of Feb 14, 2022 | 6.37% | 3.24M shares | |
| Adds to | 112.96% |
50.87M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 112.96%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
BlackRock, Inc.Institution | 8.80% | 4.47M | 13Fas of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 6.87% | 3.50M | 13Fas of Jun 30, 2026 |
Alger Associates, Inc.Strategic | 6.37% | 3.24M | 13G/Afiled Feb 14, 2022 ↗ |
Vanguard Portfolio Management LLCInstitution | 6.15% | 3.13M | 13Fas of Jun 30, 2026 |
Hood River Capital Management LLCInstitution | 5.71% | 2.91M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 24, 2026 | Karl S. Dahlquist | officer: Chief Legal Officer | −9,370 | $48.89 |
| Aug 5, 2026 | Maggie Yuen | director | −3,500 | $38.42 |
| Aug 5, 2026 | Karen Prange | director | −3,564 | $38.80 |
| Jul 29, 2026 | Justin J. Noznesky | officer: Chief Mktg & Strategy Officer | −6,182 | $38.80 |
| Jul 28, 2026 | Sven Wehrwein | director | −25,000 | $37.84 |
- Medtronic
Direct surgical rival in LAA clips and cardiac ablation
- Boston Scientific
Major LAA closure and PFA platform competitor
- Abbott
LAA occlusion and EP ablation overlap in AF care
- Johnson & Johnson
Biosense Webster PFA and mapping rival in AF ablation
- Pacira BioSciences
Cryoneurolysis and non-opioid postsurgical pain peer
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AtriCure | $53.11 | +0.93% | $2.68B | 247.8 | 351.4 | 4.7 | +12.8% |
| Medtronic | $92.50 | +0.33% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Boston Scientific | $48.45 | +0.16% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Abbott | $110.50 | +0.04% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Johnson & Johnson | $275.25 | +0.00% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Pacira BioSciences | $26.45 | −0.41% | $1.05B | 75.7 | 8.5 | 1.4 | +6.2% |
| Median | 31.9 | 15.3 | 3.4 | +7.5% |